Agnafit Bidco extends the acceptance period for the public offer to the shareholders of Sobi and announces its intention not to increase the price of SEK 235 per share in the Offer

This announcement is not an offer, whether directly or indirectly, in Australia, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled "Important information" at the end of this announcement and in the offer document and supplement offer document published on Agnafit Bidco's website (www.agnafit-offer.com). Shareholders in the United States should also refer to the section titled "Special notice to shareholders in the United States" at the end of this announcement.

Following receipt of all regulatory approvals, Agnafit Bidco extends the acceptance period for the public offer to the shareholders of Sobi and announces its intention not to increase the price of SEK 235 per share in the Offer

On 2 September 2021, Advent International Corporation^[1] ("Advent") and Aurora Investment Pte Ltd^[2] ("Aurora"), an affiliate of GIC Pte Ltd, announced through Agnafit Bidco AB^[3] ("Agnafit Bidco"), a recommended public offer to the shareholders of Swedish Orphan Biovitrum AB (publ) ("Sobi") to tender all shares in Sobi to Agnafit Bidco for SEK 235 per share (the "Offer"). An offer document was made public on 21 September 2021 and a supplement to the offer document was made public on 13 October 2021. Agnafit Bidco announced on 20 October 2021 that Agnafit Bidco had received all necessary regulatory approvals from authorities, including from competition authorities.

Tom Allen, Managing Director of Advent International Ltd, comments:

"Given the recent announcement regarding receipt of all necessary regulatory clearances, Agnafit Bidco has decided to extend the acceptance period to 4 November, to allow extended time for all remaining shareholders to tender their shares. We remain committed to our offer price of SEK 235, which we believe is very attractive. We would also like to emphasize that the offer price is best and final, which means that we cannot increase the consideration in the Offer according to applicable rules. We are encouraged by the support from Sobi’s board of directors and main shareholders, confirming our belief that Sobi’s continued transformation journey is best pursued in a private environment. Advent and Aurora, as long-term committed owners, fully stand behind Sobi’s important mission to develop and deliver innovative therapies and services to improve life for people living with rare diseases."

The shares tendered in the Offer at the end of the acceptance period on 21 October 2021 amount to in aggregate 213,169,538 shares in Sobi, corresponding to approximately 72.2 percent[4] of the share capital and the voting rights in Sobi.

As presented also in the offer announcement press release published on 2 September 2021, the price in the Offer of SEK 235 per share represents a premium of 37.7 percent compared to the volume-weighted average trading price of SEK 170.62 for the shares during the last 30 trading days ended on 25 August 2021 (the last day of trading prior to market speculation regarding a potential public offer for the Company before the announcement of the Offer) and 54.7 percent compared to the volume-weighted average trading price of SEK 151.95 for the shares during the last 90 trading days ended on 25 August 2021.

In the Offer, Agnafit Bidco reserved the right to extend the acceptance period, as well as to postpone the settlement date. In order to allow the remaining shareholders in Sobi to accept the Offer, Agnafit Bidco has resolved to extend the acceptance period until 4 November 2021 at 17:00 (CET). Settlement for shares tendered in the Offer as well as for shares tendered during the extended acceptance period is expected to be initiated on or around 12 November 2021. Agnafit Bidco reserves the right to further extend the acceptance period for the Offer as well as to further postpone the settlement date.

Agnafit Bidco has further resolved to waive the right to increase the price of SEK 235 per share in the Offer. By this statement, Agnafit Bidco cannot, in accordance with Nasdaq Stockholm's Takeover rules, increase the price in the Offer. SEK 235 per share is consequently the highest price that will be paid in the Offer.

In all other respects the terms for the Offer remain unaltered, including the conditions for completion of the Offer and the right for Agnafit Bidco to withdraw the Offer in the event it becomes clear that any of the conditions for the Offer are not satisfied or cannot be satisfied. However, with regard to conditions 2–7 as described in the offer announcement press release and in the offer document, the Offer may only be withdrawn where the non-satisfaction of such condition is of material importance to Agnafit Bidco's acquisition of Sobi or if otherwise approved by the Swedish Securities Council (Sw. Aktiemarknadsnämnden). Agnafit Bidco also reserves the right to waive, in whole or in part, one, several or all of the conditions set out in the offer announcement press release and the offer document, including, with respect to condition 1 as described in the offer announcement press release and the offer document, to complete the Offer at a lower level of acceptance.

Agnafit Bidco did not hold any financial instruments that give financial exposure to Sobi's shares at the time of the announcement of the Offer and has not acquired any such shares or financial instruments outside the Offer. Agnafit Bidco may acquire shares in Sobi in the market during the now extended acceptance period, however not at a price exceeding the price in the Offer of SEK 235 per share.

Agnafit Bidco will continue to strive towards an ownership in Sobi of more than 90 percent and thereafter initiate compulsory redemption of the remaining shares in Sobi as well as promote a de-listing of Sobi's shares from Nasdaq Stockholm.

For additional information contact:

Joachim Hörnqvist

Tel: +46 768 19 00 39, email: agnafit@fogelpartners.se

The information was submitted for publication on 25 October 2021 at 07:00 (CEST).

Information about the Offer

www.agnafit-offer.com

Important information

This press release has been published in Swedish and English. In the event of any discrepancy in content between the two language versions, the Swedish version shall prevail.

This announcement is not an offer, whether directly or indirectly, in Australia, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law (the "Restricted Jurisdiction").

The release, publication or distribution of this press release in or into jurisdictions other than Sweden may be restricted by law and therefore any persons who are subject to the laws of any jurisdiction other than Sweden should inform themselves about, and observe any applicable requirements. In particular, the ability of persons who are not resident in Sweden to accept the Offer may be affected by the laws of the relevant jurisdictions in which they are located. Any failure to comply with the applicable restrictions may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, the companies and persons involved in the Offer disclaim any responsibility or liability for the violation of such restrictions by any person.

This announcement has been prepared for the purpose of complying with Swedish law, the Takeover Rules and the Swedish Securities Council's rulings regarding interpretation and application of the Takeover Rules and the information disclosed may not be the same as that which would have been disclosed if this press release had been prepared in accordance with the laws of jurisdictions other than Sweden.

Unless otherwise determined by Agnafit Bidco or required by Swedish law, the Takeover Rules and the Swedish Securities Council's rulings regarding interpretation and application of the Takeover Rules, and permitted by applicable law and regulation, the Offer will not be made available, directly or indirectly, in, into or from a Restricted Jurisdiction or any other jurisdiction where to do so would violate the laws in that jurisdiction and no person may accept the Offer by any use, means or instrumentality (including, but not limited to, facsimile, e-mail or other electronic transmission, telex or telephone) of interstate or foreign commerce of, or of any facility of a national, state or other securities exchange of any Restricted Jurisdiction or any other jurisdiction where to do so would constitute a violation of the laws of that jurisdiction and the Offer may not be capable of acceptance by any such use, means, instrumentality or facilities. Accordingly, copies of this press release and any formal documentation relating to the Offer are not being, and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in or into or from any Restricted Jurisdiction or any other jurisdiction where to do so would constitute a violation of the laws of that jurisdiction and persons receiving such documents (including custodians, nominees and trustees) must not mail or otherwise forward, distribute or send them in or into or from any Restricted Jurisdiction or any other jurisdiction where to do so would constitute a violation of the laws of that jurisdiction.

The availability of the Offer to shareholders of Sobi who are not resident in and citizens of Sweden may be affected by the laws of the relevant jurisdictions in which they are located or of which they are citizens. Persons who are not resident in or citizens of Sweden should inform themselves of, and observe, any applicable legal or regulatory requirements of their jurisdictions.

The Offer, the information and documents contained in this press release are not being made and have not been approved by an authorised person for the purposes of section 21 of the UK Financial Services and Markets Act 2000 (the “FSMA”). Accordingly, the information and documents contained in this press release are not being distributed to, and must not be passed on to, the general public in the United Kingdom, unless an exemption applies. The communication of the information and documents contained in this press release is exempt from the restriction on financial promotions under section 21 of the FSMA on the basis that it is a communication by or on behalf of a body corporate which relates to a transaction to acquire day to day control of the affairs of a body corporate; or to acquire 50 per cent or more of the voting shares in a body corporate, within article 62 of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005.

Statements in this press release relating to future status or circumstances, including statements regarding future performance, growth and other trend projections and other benefits of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as "anticipates", "intends", "expects", "believes", or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Agnafit Bidco. Any such forward-looking statements speak only as of the date on which they are made and Agnafit Bidco has no obligation (and undertakes no such obligation) to update or revise any of them, whether as a result of new information, future events or otherwise, except for in accordance with applicable laws and regulations.

Special notice to shareholders in the United States

The Offer described in this press release is made for the issued and outstanding shares of Sobi, a company incorporated under Swedish law, and is subject to Swedish disclosure and procedural requirements, which may be different from those of the United States. The Offer is made in the United States pursuant to Section 14(e) of the U.S. Securities Exchange Act of 1934, as amended (the "U.S. Exchange Act") and Regulation 14E thereunder, to the extent applicable, and otherwise in compliance with the disclosure and procedural requirements of Swedish law, including with respect to withdrawal rights, the Offer timetable, notices of extensions, announcements of results, settlement procedures (including as regards to the time when payment of the consideration is rendered) and waivers of conditions, which may be different from requirements or customary practices in relation to U.S. domestic tender offers. The offeror’s ability to waive the conditions to the Offer (both during and after the end of the acceptance period) and the shareholders’ ability to withdraw their acceptances, may not be the same under a tender offer governed by Swedish law as under a tender offer governed by U.S. law. Holders of the shares of Sobi domiciled in the United States (the "U.S. Holders") are encouraged to consult with their own advisors regarding the Offer.

Sobi's financial statements and all financial information included herein, or any other documents relating to the Offer, have been or will be prepared in accordance with IFRS and may not be comparable to the financial statements or financial information of companies in the United States or other companies whose financial statements are prepared in accordance with U.S. generally accepted accounting principles. The Offer is made to the U.S. Holders on the same terms and conditions as those made to all other shareholders of Sobi to whom an offer is made. Any information documents, including the offer document, are being disseminated to U.S. Holders on a basis comparable to the method pursuant to which such documents are provided to Sobi's other shareholders.

The Offer, which is subject to Swedish law, is being made to the U.S. Holders in accordance with the applicable U.S. securities laws, and applicable exemptions thereunder. To the extent the Offer is subject to U.S. securities laws, those laws only apply to U.S. Holders and thus will not give rise to claims on the part of any other person. The U.S. Holders should consider that the price for the Offer is being paid in SEK and that no adjustment will be made based on any changes in the exchange rate.

It may be difficult for Sobi's shareholders to enforce their rights and any claims they may have arising under the U.S. federal or state securities laws in connection with the Offer, since Sobi and Agnafit Bidco are located in countries other than the United States, and some or all of their officers and directors may be residents of countries other than the United States. Sobi's shareholders may not be able to sue Sobi or Agnafit Bidco or their respective officers or directors in a non-U.S. court for violations of U.S. securities laws. Further, it may be difficult to compel Sobi or Agnafit Bidco and/or their respective affiliates to subject themselves to the jurisdiction or judgment of a U.S. court.

To the extent permissible under applicable law or regulations, Agnafit Bidco and its affiliates or its brokers and its brokers’ affiliates (acting as agents for Agnafit Bidco or its affiliates, as applicable) may from time to time and during the pendency of the Offer, and other than pursuant to the Offer, directly or indirectly purchase or arrange to purchase shares of Sobi outside the United States, or any securities that are convertible into, exchangeable for or exercisable for such shares. These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices, and information about such purchases will be disclosed by means of a press release or other means reasonably calculated to inform U.S. Holders of such information. In addition, the financial advisors to Agnafit Bidco may also engage in ordinary course trading activities in securities of Sobi, which may include purchases or arrangements to purchase such securities as long as such purchases or arrangements are in compliance with the applicable law. Any information about such purchases will be announced in Swedish and in a non-binding English translation available to the U.S. Holders through relevant electronic media if, and to the extent, such announcement is required under applicable Swedish or U.S. law, rules or regulations.

The receipt of cash pursuant to the Offer by a U.S. Holder may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local, as well as foreign and other, tax laws. Each shareholder is urged to consult an independent professional adviser regarding the tax consequences of accepting the Offer. Neither Agnafit Bidco nor any of its affiliates and their respective directors, officers, employees or agents or any other person acting on their behalf in connection with the Offer shall be responsible for any tax effects or liabilities resulting from acceptance of this Offer.

NEITHER THE U.S. SECURITIES AND EXCHANGE COMMISSION NOR ANY U.S. STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THE OFFER, PASSED ANY COMMENTS UPON THE MERITS OR FAIRNESS OF THE OFFER, PASSED ANY COMMENT UPON THE ADEQUACY OR COMPLETENESS OF THIS PRESS RELEASE OR PASSED ANY COMMENT ON WHETHER THE CONTENT IN THIS PRESS RELEASE IS CORRECT OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE IN THE UNITED STATES.